Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study

Schena, Marina; Barone, C.; Birocco, Nadia; Dongiovanni, Diego; Numico, Gianmauro; Colantonio, I.; Bertetto, Oscar

doi:10.1007/s00280-004-0875-1

Cited by 11 publications

(8 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, patients with recurrent and/or metastatic SCCHN respond poorly to many single agent treatments [4,22,[25][26][27][28][29]. Trials in heavily pretreated, metastatic SCCHN involving combination regimens of standard therapies such as cisplatin, 5-fluorouracil, and/or taxanes have been associated with higher response rates [5,[30][31][32][33]. However, the outcome/ survival of these patients has remained poor, and there is considerable room for improvement in the treatment of recurrent and/or metastatic SCCHN patients.…”

Section: Discussionmentioning

confidence: 99%

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

et al. 2007

View full text Add to dashboard Cite

This phase II trial was initiated to assess the efficacy and safety of oral vorinostat (Zolinza, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Eligible patients must have recurrent and/or metastatic head and neck cancer unresponsive to or intolerant of conventional chemotherapy. Patients must have measurable disease, adequate hematologic, hepatic, and renal function, and be able to swallow capsules. Four or more weeks must have elapsed since prior chemotherapy, radiation therapy, major surgery or investigational anticancer therapy, and patients must have recovered from prior toxicities. Study endpoints included response rate, duration of stable disease and progression-free survival. Thirteen patients were enrolled (9 males); 1 withdrew consent prior to starting therapy. Twelve patients received oral vorinostat 400 mg once daily and were evaluable for response. The median age was 54 years (range 40-82). All patients had received prior chemotherapy (including 10 with platinum- or taxane-based combination therapy), and 9 had prior radiation therapy. No confirmed partial or complete responses were observed. One unconfirmed partial response was seen. Three patients had stable disease ranging from 9 to 26 weeks. Nine patients discontinued due to progressive disease, two withdrew consent, and one discontinued therapy for grade 3 anorexia. Grades 3-4 drug-related toxicities included thrombocytopenia (n=3), anorexia (n=2), and dehydration (n=2). Oral vorinostat 400 mg qd was generally well tolerated but did not demonstrate efficacy as defined by tumor response in this small group of heavily pre-treated patients.

show abstract

Section: Discussionmentioning

confidence: 99%

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

et al. 2007

View full text Add to dashboard Cite

show abstract

“…Adherence rates are sometimes noted in reports of clinical trials but otherwise data are scarce. In the context of trials, rates are often between 70% and 90% (Schena et al, 2005). On the surface, this is encouraging and suggests little problem, however, one must consider the abundant support available to trial participants and the lengths researchers go to prevent attrition.…”

Section: Common Treatment Optionsmentioning

confidence: 94%

Treatment Adherence in Head and Neck Cancer Patients Undergoing Radiation Therapy: Challenges for Nursing

Edmonds

McGuire

2007

Journal of Radiology Nursing

View full text Add to dashboard Cite

“…However, for advanced HNSCC, comprehensive therapies including chemotherapy, surgery, radiotherapy, and their combinations are needed. Even after the combined therapies, the 3-year and 5-year survival rates have been found to be between 30%–50% and 10%–30%, respectively 2–4. Moreover, studies also found that local recurrence and distant metastasis rates in these patients were between 50%–60% and 20%–30%, respectively 2,4.…”

Section: Introductionmentioning

confidence: 99%

“…Even after the combined therapies, the 3-year and 5-year survival rates have been found to be between 30%–50% and 10%–30%, respectively 2–4. Moreover, studies also found that local recurrence and distant metastasis rates in these patients were between 50%–60% and 20%–30%, respectively 2,4. It has been shown that patients with recurrent and metastatic HNSCC are very difficult to treat and have very unfavorable prognoses 5.…”

Section: Introductionmentioning

confidence: 99%

“…Combination therapies of taxanes, platinum-based drugs, and 5-Fu have been confirmed to be more effective to treat HNSCC than other chemotherapies and have been recognized as first-line chemotherapy 9–12. However, after palliative treatment, the median OS and tumor ORR were only 9–11 months, and 44%, respectively, for patients with recurrent and metastatic HNSCC 4,13. Therefore, it is of great significance to explore new and effective therapies for patients with recurrent and metastatic HNSCC in order to improve their survival time and quality of life.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Chen¹,

Cheng²,

Yang³

et al. 2013

OTT

View full text Add to dashboard Cite

BackgroundChronomodulated chemotherapy has emerged as a new therapy as a result of recent studies focusing on the biological clock. It has been demonstrated that combination chronomodulated chemotherapy of platinum-based drugs and 5-fluorouracil (5-Fu) can significantly improve efficacy and reduce the incidence of adverse events in patients with metastatic colorectal cancer, as compared with conventional chemotherapy. However, the results may be different in different tumors. Recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) is very difficult to treat, with an extremely unfavorable prognosis. So far, no report is available on chronomodulated chemotherapy for HNSCC.MethodsRetrospective analyses were made on 49 patients with local recurrent and/or metastatic HNSCC who underwent palliative treatments with paclitaxel, carboplatin, and 5-Fu. The patients were divided into a chronomodulated chemotherapy group (28 patients) and a conventional chemotherapy group (21 patients) according to their administration times. The two groups were compared for tumor objective response rate, overall survival (OS), progression-free survival (PFS), and the incidence of adverse events.ResultsThe tumor objective response rate and patients’ OS were significantly higher and longer in the chronomodulated chemotherapy group than in the conventional chemotherapy group (71.43% versus 42.86%, respectively, P<0.05; and median OS 15.3 months versus 10.6 months, respectively, P<0.05). However, PFS was similar statistically (median PFS 11.6 months versus 7.2 months, P>0.05). The global incidence of adverse events in the chronomodulated chemotherapy group was significantly lower than that in the conventional chemotherapy group (46.43% versus 76.19%, P<0.05), with significantly lower incidence of grade 3–4 adverse events (7.14% versus 33.33%, P<0.05).ConclusionChronomodulated chemotherapy with paclitaxel, carboplatin, and 5-Fu may be a new and effective therapy for patients with recurrent and/or metastatic HNSCC as compared with conventional chemotherapy.

show abstract

Weekly cisplatin paclitaxel and continuous infusion fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma: a phase II study

Abstract: A weekly schedule of cisplatin and paclitaxel associated with continuous infusion 5-FU showed low toxicity in the treatment of advanced HNSCC while significant activity was conserved.

Cited by 11 publications

References 21 publications

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer

Treatment Adherence in Head and Neck Cancer Patients Undergoing Radiation Therapy: Challenges for Nursing

Retrospective analysis of chronomodulated chemotherapy versus conventional chemotherapy with paclitaxel, carboplatin, and 5-fluorouracil in patients with recurrent and/or metastatic head and neck squamous cell carcinoma

Contact Info

Product

Resources

About